Oncobiotek Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.30 M
as on 28-12-2024
- Satisfied Charges ₹ 5.23 M
as on 28-12-2024
- Revenue 8.12%
(FY 2022)
- Profit -76.10%
(FY 2022)
- Ebitda -14.80%
(FY 2022)
- Net Worth 14.45%
(FY 2022)
- Total Assets -21.83%
(FY 2022)
About Oncobiotek Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.30 M. The company has closed loans amounting to ₹5.23 M, as per Ministry of Corporate Affairs (MCA) records.
Haresh Khetwani and Rajesh Sharma serve as directors at the Company.
- CIN/LLPIN
U24230GJ2014PTC079996
- Company No.
079996
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Oncobiotek Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Sharma  | Director | 03-Jul-2014 | Current |
| Haresh Khetwani | Director | 03-Jul-2014 | Current |
Financial Performance of Oncobiotek Drugs.
Oncobiotek Drugs Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.12% increase. The company also saw a substantial fall in profitability, with a 76.1% decrease in profit. The company's net worth Soared by an impressive increase of 14.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncobiotek Drugs?
In 2021, Oncobiotek Drugs had a promoter holding of 38.00% and a public holding of 62.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oncobiotek Formulations Private LimitedActive 6 years 7 monthsHaresh Khetwani and Rajesh Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Bhagyodaya Co-Operative Bank Limited Creation Date: 02 Mar 2015 | ₹1.30 M | Open |
Others Creation Date: 12 Jul 2017 | ₹1.88 M | Satisfied |
Others Creation Date: 12 Jul 2016 | ₹1.00 M | Satisfied |
How Many Employees Work at Oncobiotek Drugs?
Oncobiotek Drugs has a workforce of 8 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncobiotek Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncobiotek Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
